

Thyroid cancer

[E] Evidence review for efficacy of repeat FNAC, active surveillance, or discharge

NICE guideline <number>

Evidence reviews underpinning recommendation 1.2.15 in the NICE guideline

June 2022

Draft for Consultation

*These evidence reviews were developed
by National Guideline Centre*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE [Year of publication]. All rights reserved. Subject to Notice of rights.

ISBN:

Contents

1	Repeat testing in people with benign or non-diagnostic FNAC	5
1.1	Review question	5
1.1.1	For people with fine-needle aspiration samples showing benign cytology or non-diagnostic features but with US / clinical findings indicative of increased risk of malignancy, is it clinically and cost effective to use diagnostic hemithyroidectomy, repeat FNAC, use active surveillance or discharge?	5
1.1.2	Introduction	5
1.1.3	Summary of the protocol	5
1.1.4	Methods and process	6
1.1.5	Effectiveness evidence	6
1.1.6	Summary of studies included in the effectiveness evidence	6
1.1.7	Summary of the effectiveness evidence	6
1.1.8	Economic evidence	6
1.1.9	Summary of included economic evidence	7
1.1.10	Economic model	9
1.1.11	Economic evidence statements	13
1.1.12	The committee's discussion and interpretation of the evidence	13
1.1.13	Recommendations supported by this evidence review	16
	References	17
	Appendices	20
	Appendix A – Review protocols	20
	Appendix B – Literature search strategies	30
	Appendix C – Effectiveness evidence study selection	40
	Appendix D – Effectiveness evidence	41
	Appendix E – Forest plots	42
	Appendix F – GRADE and/or GRADE-CERQual tables	43
	Appendix G – Economic evidence study selection	44
	Appendix H – Economic evidence tables	45
	Appendix I – Excluded studies	47

1 Repeat testing in people with benign or non-diagnostic FNAC

3 1.1 Review question

4 1.1.1 For people with fine-needle aspiration samples showing benign cytology or
5 non-diagnostic features but with US / clinical findings indicative of increased
6 risk of malignancy, is it clinically and cost effective to use diagnostic
7 hemithyroidectomy, repeat FNAC, use active surveillance or discharge?

8 1.1.2 Introduction

9 The vast majority of thyroid nodules are the result of a benign process, however, thyroid
10 cancer also, typically, presents as a thyroid nodule. In recent years, ultrasound examination
11 of the thyroid has become the standard of care for the initial investigation of thyroid nodules,
12 and where ultrasound shows any features, which are indeterminate or suspicious for
13 malignancy, fine needle aspiration biopsy is undertaken.

14 Where the cytology is suggestive of a benign diagnosis, uncertainty then remains regarding
15 the underlying reason for the indeterminate or suspicious features on ultrasound and the
16 most appropriate further management to ensure that thyroid malignancy, when present, is
17 diagnosed in a timely fashion, to prevent adverse patient outcomes. The current practice in
18 most centres is to repeat an inadequate or benign FNA if the US/clinical features suggest
19 increased risk of malignancy. This review seeks to determine the best management strategy
20 for people with benign or inadequate findings on FNAC that are in conflict with the prior
21 ultrasound results that suggest a risk of malignancy.

22

23 1.1.3 Summary of the protocol

24 For full details see the review protocol in Appendix A.

25 Table 1: PICO characteristics of review question

Population	People aged 16 or over who are suspected of having thyroid cancer. They have fine-needle aspiration samples showing benign cytology or non-diagnostic atypical features but have US / clinical findings indicative of increased risk of malignancy
Interventions	<ul style="list-style-type: none">• diagnostic hemithyroidectomy• repeat FNAC• active surveillance• discharge without active surveillance
Comparison	Each other
Outcomes	<ul style="list-style-type: none">• mortality• quality of life (any validated scores)• thyroid cancer diagnosis
Study design	<ul style="list-style-type: none">• Systematic reviews• RCTs

1 **1.1.4 Methods and process**

2 This evidence review was developed using the methods and process described in
3 [Developing NICE guidelines: the manual](#). Methods specific to this review question are
4 described in the review protocol in appendix A and the methods document.

5 Declarations of interest were recorded according to [NICE's conflicts of interest policy](#).

6 **1.1.5 Effectiveness evidence**

7 **1.1.5.1 Included studies**

8 No relevant clinical studies comparing management strategies for people with indeterminate
9 FNA were identified.

10 See also the study selection flow chart in Appendix C, study evidence tables in Appendix D,
11 forest plots in Appendix E and GRADE tables in Appendix F.

12 **1.1.5.2 Excluded studies**

13 Fifteen studies were identified for full text eligibility assessment. Of these, 11 were narrative
14 reviews or systematic reviews. All references were checked for potential inclusion however
15 none were RCTs. Of the remaining 4, 3 studies were excluded due to having an incorrect
16 study design (for example, non-randomised or no comparison group) and 1 was excluded as
17 the population was unclear and the intervention was not included in the protocol.

18 See the excluded studies list in Appendix I.

19 **1.1.6 Summary of studies included in the effectiveness evidence**

20 No evidence was identified.

21 **1.1.7 Summary of the effectiveness evidence**

22 No evidence was identified.

23 **1.1.8 Economic evidence**

24 **1.1.8.1 Included studies**

25 One health economic study with the relevant comparison was included in this review.² This is
26 summarised in the health economic evidence profile below (**Table 2**) and the health
27 economic evidence table in Appendix H.

28 **1.1.8.2 Excluded studies**

29 One health economic study was excluded due to assessment of limited applicability or
30 methodological limitations.³⁰ This is listed in Appendix I, with reasons for exclusion given.

31 See also the health economic study selection flow chart in Appendix G.

1 1.1.9 Summary of included economic evidence

2 Table 2: Health economic evidence profile: Repeat FNAC, active surveillance or discharge

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Furlan 2005 ² ([Canada])	Partially applicable ^(a)	Potentially serious limitations ^(b)	<ul style="list-style-type: none"> Retrospective database analysis Cost-consequence analysis Population: Adults with suspected differentiated thyroid cancer and non-diagnostic or benign findings following FNA biopsy Comparators: <ol style="list-style-type: none"> Single FNA biopsy (includes the first cytological evaluation from individuals who later underwent sequential FNA biopsies. Sequential FNA biopsy (at least 2 cytological aspirations from the same patient on different dates over ≥1 year) Follow-up: 2 years 	2-1: £33 ^(c)	2-1: <ul style="list-style-type: none"> Accuracy: 14.4% Sensitivity: 10.2% Specificity: 4.3% 		Exclusion of all incidental microcarcinomas of 10mm or less found after thyroidectomy did not result in any significant differences in diagnostic accuracy (p=0.898); sensitivity (p=0.965); or specificity (0.594).

3 Abbreviations: ICER = incremental cost-effectiveness ratio; FNAC = Fine-needle aspiration cytology; NA = not applicable; NR = not reported; QALYs= quality-adjusted life
4 years.

5 (a) Canadian healthcare context. Discount rate was not reported for a study with a time horizon of 2 years. QALYs were not reported.

6 (b) Patients were not randomized to treatment groups and had statistically significant differences in baseline patient characteristics between groups. Mortality, quality of life, and
7 other patient outcomes were not included. Study is non-randomized, sample size is small and study was conducted at one hospital with unclear generalizability. Analysis did
8 not include costs of surgery and other downstream costs and consequences of diagnosis. Cost year not specified; assumed to be the date of the published source used to
9 obtain unit costs. Sensitivity analyses were not included. Relatively old study: accuracy of FNAC may have been improved in the last two decades.

1

(c) 2004 Canadian dollars converted to 2004 UK pounds.¹⁷. Cost components incorporated: FNA biopsy

1 1.1.10 Economic model

2 A health economic model was developed to assess the cost-effectiveness of several
3 diagnostic pathways for people who received a non-diagnostic (Thy1) or indeterminate
4 (Thy3a and Thy3f) cytology. The full economic report can be viewed in the economic report
5 published alongside the guideline

6 Population and strategies

7 Three population with different cancer prevalence were included in the analysis: Thy1, Thy3a
8 and Thy3f. The strategies included are different for each cytology:

- 9 • Non-diagnostic Thy1
 - 10 ○ Repeat FNAC and selective use of diagnostic hemithyroidectomy (current
 - 11 practice)
 - 12 ○ Core needle biopsy (CNB) and selective use of diagnostic hemithyroidectomy
 - 13 ○ Routine use of diagnostic hemithyroidectomy
- 14 • Indeterminate Thy3a
 - 15 ○ Repeat FNAC and selective use of diagnostic hemithyroidectomy (current
 - 16 practice)
 - 17 ○ Repeat FNAC and selective use of molecular testing
 - 18 ○ CNB and selective use of diagnostic hemithyroidectomy
 - 19 ○ CNB and selective use of molecular testing
 - 20 ○ Routine use of molecular testing
 - 21 ○ Routine use of diagnostic hemithyroidectomy
- 22 • Indeterminate Thy3f
 - 23 ○ Routine use of diagnostic hemithyroidectomy (current practice)
 - 24 ○ Routine use of molecular testing

25 Molecular testing is not clinically indicated for people with a non-diagnostic Thy1, therefore it
26 was not included for this population. Likewise, repeat sampling with FNAC or CNB is rarely of
27 any use after Thy3f, so CNB and FNAC strategies were not included for Thy3f.

28 A cost-utility analysis was undertaken where quality-adjusted life years (QALYs) and costs
29 from a current UK NHS and personal social services perspective were considered. The
30 analysis was run each time separately for each cytology.

31 Model structure

- 32 • Two decision trees and one Markov model with 50 cycles were developed to estimate
33 costs and consequences of each strategy
- 34 • Each diagnostic strategy had its own decision decision tree that was used to estimate
35 the number of people ending up with a correct diagnosis, a missed diagnosis or an
36 avoidable hemithyroidectomy.
- 37 • A second decision tree was used to determine the outcomes of surgery
38 (hemithyroidectomy or completion thyroidectomy for people with malignancy). The
39 possible outcomes are: dead, no complications, recurrent laryngeal nerve (RLN)
40 injury, transient or permanent hypoparathyroidism, re-admission
- 41 • Depending on the outcomes of the surgical and diagnostic decision tree, people enter
42 the Markov model in a specific state characterized by whether the node was benign
43 or malignant, whether the cancer was misdiagnosed, whether the person received
44 surgery, and whether surgery caused one of the two long-term complications:
45 recurrent laryngeal nerve (RLN) injury and hypoparathyroidism.
- 46 • The Markov model was utilized to estimate long-term consequences of cancer, risk of
47 recurrence and long-term costs of monitoring and health states.

- People with malignant nodules are at a risk of recurrence during each cycle, with a higher probability if their diagnoses was missed or the cancer is untreated, thus moving to a new state representing the progressed state of disease. This state is characterized by a higher cost, lower QoL and higher mortality

Data sources

- Accuracy data were estimated from the studies included in 1.5 review with the addition of external meta-analysis and studies when necessary. These were four studies on the accuracy of molecular tests^{16, 18 10, 22} that were assessed through QUADAS tables and a meta-analysis on repeat sampling with FNAC or CNB¹⁹
- Surgery outcomes were taken from the latest BAETS audit²⁶
- Recurrence rates were informed from HiLo trial¹²
- Mortality in the recurrent states or after a complication was estimated using published studies comparing people with recurrence or complication with the general population
- Disutility factors associated with each complication or adverse event were calculated using the study from Kebebew 2005⁷

Cost

- The price of the molecular tests were, when possible, obtained from the manufacturers or, alternatively, estimated from a published study⁹. Costs of sample packaging and shipping were also included
- Cost of FNAC and CNB were collected from the NHS Reference Costs 2019-2020¹⁵
- The costs of a hemithyroidectomy, completion thyroidectomy and total thyroidectomy were estimated using NHS Reference Costs combined with LOS data from BAETS audit²⁶
- The cost associated with surgery complications and radioactive iodine ablation (RAI) were estimated using BNF⁶ and PCA⁵ for pharmaceutical costs, and NHS Reference Costs 2019-2020¹⁵ for healthcare costs
- Thyroid hormone replacement costs were calculated using BNF⁶ and PCA⁵
- The costs of the various tests needed for post-surgery monitoring were informed from NICE thyroid disease guideline¹⁴ and NHS Reference Costs 2019/2020¹⁵

Results

The results for the non-diagnostic cytology Thy1 are illustrated in **Table 3**.

Table 3: Diagnostic performance – Thy1 (probabilistic)

Strategy	Cost per patient	QALYs per patient	NMB (£20,000)	Probability 1st ranked
Repeat FNAC & HT	£2,094 (£1,570 to £2,826)	17.17 (16.79 to 17.35)	£341,346 (£333,310 to £345,253)	2%
CNB & HT	£1,815 (£1,223 to £2,600)	17.18 (16.81 to 17.36)	£341,874 (£333,729 to £345,965)	98%
HT	£3,018 (£2,586 to £3,617)	17.13 (16.77 to 17.31)	£339,608 (£331,841 to £343,456)	0%

Abbreviations: CNB = core needle biopsy; FNAC = fine needle aspiration cytology; HT = hemithyroidectomy; NMB = net monetary benefit; QALY = quality-adjusted life year

1 In almost all simulations CNB was the most cost-effective strategy compared with repeat
2 FNAC and hemithyroidectomy. None of the scenario analysis altered the conclusions.

3 **Table 8** shows the probabilistic results for the indeterminate category Thy3a.

4 **Table 4: Diagnostic performance – Thy3a (probabilistic)**

Strategy	Cost per patient	QALYs per patient	NMB (£20,000)	Probability 1st ranked
Afirma-GSC	£5,318 (£4,830 to £5,879)	16.88 (16.28 to 17.20)	£332,198 (£319,779 to £338,890)	0%
ThyroSeq V3	£3,819 (£3,339 to £4,529)	16.87 (16.27 to 17.20)	£333,658 (£321,259 to £340,376)	0%
ThyGenx/Thyra MIR	£4,759 (£4,243 to £5,349)	16.88 (16.24 to 17.21)	£332,741 (£319,806 to £339,693)	0%
ThyroSeq V1	£4,045 (£3,500 to £4,653)	16.80 (16.15 to 17.17)	£332,013 (£318,665 to £339,586)	0%
FNAC & HT	£3,078 (£2,629 to £3,601)	16.90 (16.33 to 17.20)	£334,992 (£323,115 to £341,241)	18%
FNAC & MT ^(a)	£3,089 (£2,620 to £3,638)	16.90 (16.32 to 17.20)	£334,902 (£322,854 to £341,278)	18%
CNB & HT	£3,018 (£2,542 to £3,573)	16.90 (16.33 to 17.21)	£335,079 (£323,131 to £341,372)	34%
CNB & MT ^(a)	£3,025 (£2,527 to £3,597)	16.90 (16.32 to 17.21)	£335,021 (£322,989 to £341,380)	30%
HT	£3,784 (£3,400 to £4,247)	16.89 (16.32 to 17.19)	£333,935 (£322,279 to £340,139)	0%

5 *Abbreviations: CNB = core needle biopsy; FNAC = fine needle aspiration cytology; HT = hemithyroidectomy; MT*
6 *= molecular testing*

7 *(a) The molecular test in FNAC & MT and CNB & MT strategies is ThyroSeq V3*

8 In none of the simulations routine use of molecular testing or routine hemithyroidectomy were
9 found to be cost-effective. The two CNB strategies were more likely to be cost-effective
10 compared with repeat FNAC strategies: 64% vs 36%. Comparing CNB and selective use of
11 molecular testing (ThyroSeq V3) with CNB and selective use of hemithyroidectomy, the latter
12 was found to be cheaper and slightly more effective, making it more cost-effective. Moreover,
13 CNB and selective use of hemithyroidectomy was the most cost-effective strategy in a higher
14 number of simulations compared to CNB and selective use of hemithyroidectomy (34% vs
15 30%).

The scenario analysis showed that when a lower prevalence of cancer was assumed and when the disutility associated with cancer recurrence was applied for one cycle only, CNB and selective use of molecular testing becomes the most cost-effective strategy.

Table 5 shows the probabilistic results for the indeterminate category Thy3f.

Table 5: Diagnostic performance – Thy3f (probabilistic)

Strategy	Cost per patient	QALYs per patient	NMB (£20,000)	Probability 1st ranked
Afirma-GSC	£5,867 (£5,223 to £6,609)	16.69 (15.87 to 17.12)	£327,882 (£310,894 to £336,889)	0%
ThyroSeq V3	£4,452 (£3,820 to £5,195)	16.78 (16.02 to 17.17)	£331,215 (£315,631 to £339,366)	57%
ThyGenx/ThyraMIR	£5,014 (£4,335 to £5,801)	16.60 (15.64 to 17.12)	£326,888 (£307,388 to £337,730)	1%
ThyroSeq V1	£4,485 (£3,800 to £5,271)	16.65 (15.81 to 17.11)	£328,601 (£311,248 to £338,006)	1%
HT	£4,137 (£3,630 to £4,765)	16.77 (16.03 to 17.15)	£331,361 (£316,111 to £339,142)	40%

Abbreviations: HT = hemithyroidectomy; NMB = net monetary benefit; QALY = quality-adjusted life year

Although routine use of molecular testing with GSC test ThyroSeq V3 was more likely to be cost-effective, routine use of hemithyroidectomy had a slightly higher average NMB suggesting that molecular testing had a higher degree of uncertainty compared with diagnostic hemithyroidectomy: whereas accuracy and feasibility of molecular testing in England is unclear, hemithyroidectomy has always 100% sensitivity and specificity. The scenario analysis found the results to be very dependent on the assumptions on the cost of molecular tests: when a higher price was used or when an additional FNAC was deemed necessary to extract the sample, routine use of diagnostic hemithyroidectomy became cost-effective instead.

Two threshold analyses on the cost of molecular tests and risk of malignancy (ROM) were conducted for Thy3a and Thy3f cytologies. Selective use of molecular tests after CNB became cost-effective for Thy3a when the prices drop between £1,500 (ThyGenX/ThyraMIR) and £1,100 (Afirma-GCS). ThyroSeq V3 has a price of £1,407 which is above its threshold price of £1,200 explaining why it was not found to be cost-effective in England. Only ThyroSeq V3 was found to be potentially cost-effective in England when its price drops below £1,500. This is just above the estimated price of £1,407 which explains the uncertainty of its cost-effectiveness in this cytology.

The threshold analysis on ROM found a threshold ROM of 23% and 35% for, respectively, CNB and selective use of molecular testing in Thy3a and routine use of molecular testing in Thy3f. These are very similar to the estimated cancer prevalence in these two categories, 25% in Thy3a and 31% in Thy3f, suggesting that even a slight change in the prevalence of cancer in one of these two cytologies may change the conclusion of this analysis.

1 **1.1.11 Economic evidence statements**

- 2
- 3 • One cost-consequence analysis found sequential FNAC to be more costly but more
- 4 accurate compared to single FNAC in people with non-diagnostic or benign cytology. The
- 5 analysis was assessed as partially applicable with potentially serious limitations.
- 6 • One original cost-utility analysis found CNB to dominate repeat FNAC and diagnostic
- 7 hemithyroidectomy in people with non-diagnostic Thy1 and indeterminate Thy3a
- 8 cytologies. The analysis was assessed as directly applicable with minor limitations.

8 **1.1.12 The committee's discussion and interpretation of the evidence**

9 **91.1.12.1 The outcomes that matter most**

10 The outcomes considered for this review were mortality, health related quality of life, and

11 thyroid cancer diagnosis. For purposes of decision-making all outcomes were equally

12 regraded as being of critical importance. No evidence was identified for any of these

13 outcomes as no relevant articles were included in the review.

14 **141.1.12.2 The quality of the evidence**

15 No evidence was included in the review.

16 **161.1.12.3 Benefits and harms**

17 This section discusses all options for management following the initial FNAC results. It draws

18 on data from this review, the review on the initial FNAC tests (evidence report D), the review

19 on molecular testing (evidence report F) and committee consensus to make

20 recommendations. No evidence was identified for repeat FNAC or molecular testing and the

21 committee used a mixture of the evidence from the diagnostic accuracy review, the results

22 from the diagnostic economic model and consensus to make recommendations. The

23 committee agreed that although the evidence in report D is indirect evidence for this review,

24 they did not anticipate the accuracy would be that different for repeat testing. They were

25 happy to use it in the model.

26 Overall, the committee agreed that once the initial results from FNAC are reported it is

27 common practice to do further testing of inadequate (Thy 1), benign (Thy2) and

28 indeterminate (Thy 3) results to confirm diagnosis and avoid unnecessary surgery where

29 possible. While FNAC is the test used following initial ultrasound the committee agreed that

30 other options may offer a better management strategy when repeating tests.

31 Results that are suspicious of malignancy (Thy 4) or malignant (Thy 5) usually go straight to

32 exploratory surgery.

33 **Thy1 - inadequate FNAC results**

34 A Thy1 (inadequate) result is one where insufficient aspirate is available to permit any

35 diagnosis – there is effectively a dearth of information. In such a case there is a clear need to

36 offer repeat sampling and the committee agreed that this should be with either core needle

37 biopsy, or FNAC if core needle biopsy is unavailable. The committee recognised that core

38 biopsy was the preferred option for repeating non-diagnostic FNAC attempts, because they

39 may be less prone to inadequate results. However, if this second attempt were also

40 unsuccessful the committee recommended that the patient should be sent for a diagnostic

41 hemithyroidectomy. This was made by consensus, on the basis that there had to be a limit to

42 the number of repeated attempts, the number of such cases would be small, and that

43 sending for surgery would be the most conservative and safe approach.

44 **Thy 2 – benign FNAC results**

1 Despite the superiority of the result for smear, cytospin and cellblock (at the threshold of
2 Bethesda III and above, equivalent to Thy 3a and above) relative to other analyses, the
3 committee were concerned that the sensitivity level of 0.937 would lead to 6.3% of people
4 with malignancy being missed. Calculation of the negative predictive value at the sensitivity
5 of 0.937 and the specificity of 0.825, at our estimated prevalence of malignancy in people
6 having FNAC of 11%, yielded a value of 0.991. This indicated that only 0.9% of people with a
7 Thy 2 (benign) FNAC grade would have a true malignancy. At first sight, this ameliorated
8 some of the concern, but on reflection it was realised that this favourable result was an
9 artefact of the low prevalence of malignancy overall, and did not alter the fact that amongst
10 those people with malignancy a significant proportion would remain undetected. However, a
11 solution to this problem was provided through discussion of how failure to detect a truly
12 malignant nodule may be partly mediated by random sampling error, where the aspirated
13 sample, by chance, does not represent the population of predominantly malignant cells in the
14 nodule. If this is the case, repetition of the aspiration is unlikely to lead to a second such error
15 as the probability of two such errors occurring together would be subject to the multiplicative
16 law. For example, a 0.1 probability of such an event happening once would imply only a 0.01
17 probability of two such consecutive events. Therefore, the committee suggested, by
18 consensus, that a way of improving the sensitivity would be to repeat the ultrasound after any
19 benign (Thy2) FNAC readings in those people who had been selected for FNAC based on
20 suspicious US findings. These could be legitimately regarded as people in whom there were
21 good ultrasonographic reasons to doubt the verisimilitude of the FNAC result. The committee
22 agreed that this is in line with current practice. If the second ultrasound was positive, then
23 repeat sampling should be done by FNAC or core needle biopsy (CNB). If a benign reading
24 were found on the CNB or second FNAC result this would confirm the original FNAC result,
25 but if a malignant reading were found on the CNB or second FNAC result this would strongly
26 suggest initial sampling error and allow replacement of the original FNAC result, thereby
27 improving sensitivity. The committee discussed how this would not represent a change in
28 current practice and so would not necessarily introduce new costs.

29 **Thy 3a - indeterminate**

30 For any indeterminate result an additional sample should be offered to establish whether the
31 nodule was malignant or not. The committee agreed that sampling should be repeated with
32 CNB (or FNAC if CNB is unavailable). The committee noted that Thy3a findings can often
33 appear by chance in people that may often show Thy2 findings on a repeat sampling with
34 CNB or FNAC. Therefore, this approach would maximise specificity whilst ensuring that
35 those who show a repeat Thy3a finding (or possibly a worse grading) are appropriately
36 managed with surgery. If the result is still Thy 3a, the committee agreed that diagnostic
37 hemithyroidectomy or active surveillance should be considered. While they noted that most
38 people would not have a malignancy in this group and active surveillance could be an option,
39 they also agreed that a minority of people may have malignancy and diagnostic accuracy
40 would be the best approach should this be suspected.

41 **Thy 3f - indeterminate, Thy 4 and Thy 5 – malignant or suspicion of malignancy**

42 If Thy 3f, 4 or 5 were obtained (equivalent to Bethesda IV, V and VI) then surgery should be
43 considered. The recommendations for Thy 3f, 4 and 5 were based on extrapolation of the
44 diagnostic accuracy evidence that these groups would contain a large quantity of people with
45 malignancy, and that failure to send them for surgery would risk missing people with
46 malignancy. Although the economic model suggested molecular testing could be cost
47 effective in Thy 3f the committee agreed that that repeat sampling is less useful. Diagnostic
48 hemithyroidectomy is justified by the high risk of malignancy in this group (around 30%).
49 There were also concerns that, if not followed up with surgery, final diagnosis after Thy 3f
50 could take longer to happen. This would delay treatment for a potentially malignant tumour,
51 create uncertainty for the person, and in some centres lead to a longer delay than is allowed
52 by NHS cancer targets.

1 The committee discussed how the type of surgery undertaken would depend upon the FNAC
2 grade, as well as other information. For FNAC grades denoting a higher probability of
3 malignancy, such as Thy 4 and Thy 5, surgery would be undertaken with the assumption that
4 malignancy was probably present, involving a hemi-thyroidectomy, total thyroidectomy or
5 isthmectomy, possibly combined with central and/or lateral neck dissection, according to the
6 clinical circumstances. However, for Thy 3a and Thy 3f, where there would be greater doubt
7 about the likelihood of malignancy, and particularly for Thy1, where the probability of
8 malignancy would be low, the surgery would be performed initially for diagnostic reasons,
9 and a hemi thyroidectomy or isthmectomy would be preferred.

101.1.12.4 1.1.12.4 Cost effectiveness and resource use

11 One health economics evidence was included. This was a cost consequence analysis on
12 offering sequential FNAC (at least 2) instead of single FNAC to people with suspected
13 thyroid cancer.

14 The analysis was assessed to be partially applicable as it was conducted in Canada.
15 Moreover, the analysis had potentially serious limitations due to being not randomized and
16 relying on very old sources. The analysis showed that at an increased price of £46,
17 sequential FNAC increases the sensitivity by 10.2% and specificity by 4.2% compared to
18 single FNAC.

19 There was no included study in the clinical review. The committee agreed that understanding
20 the optimal diagnostic pathway for people who received a non-diagnostic or indeterminate
21 FNAC was extremely important in England. Around 30% of FNAC samples result in an
22 indeterminate cytology (Thy3a and Thy3f), and between 5 to 10% are non-diagnostic.
23 Assuming 5,600 fine-needle aspirations performed by the NHS every year, as per the latest
24 NHS Reference Costs 2019/2020, around 2,000 of those would require further management.
25 Hence, any recommendation changing current practice would likely require a large use of
26 NHS resource. Therefore, an economic plan to look at the most cost-effective diagnostic
27 pathway after a non-diagnostic (Thy1) or indeterminate cytology (Thy3a or Thy3f) was
28 approved by the committee and a lifetime model was developed incorporating several
29 strategies: for the non-diagnostic cytology Thy1, current practice of repeat FNAC and
30 selective use of hemithyroidectomy was compared with core-needle biopsy (CNB) and
31 selective use of hemithyroidectomy and routine use of hemithyroidectomy; for the
32 indeterminate category Thy3a, current practice of repeat FNAC and selective use of
33 hemithyroidectomy was compared with FNAC and selective use of molecular testing, CNB
34 and selective use of hemithyroidectomy and molecular testing, routine hemithyroidectomy,
35 and routine molecular testing; for the other indeterminate category Thy3f, the committee
36 were aware that repeat FNAC or CNB can rarely be beneficial, therefore the analysis
37 compared current practice (routine hemithyroidectomy) with routine molecular testing only.

38 The full economic model can be viewed in the Economic Report. The model found CNB cost
39 effective in people who received Thy1 compared to the two alternatives, repeat FNAC and
40 diagnostic hemithyroidectomy. In the probabilistic analysis, CNB had a higher Net Monetary
41 Benefit (NMB) than repeat FNAC and a very high probability of being cost-effective: 99%. In
42 none of the 10,000 Monte Carlo simulation hemithyroidectomy managed to be the most cost-
43 effective strategy, which was widely expected by the committee as ROM in Thy1 is too low to
44 justify a diagnostic surgery. The committee noted that, in some cases, a CNB may indeed be
45 more useful than a FNAC as it is able to extract more materials and could reach a final
46 diagnosis easier. This was confirmed by the clinical review of initial FNAC (evidence report
47 F) that found an extremely high sensitivity and specificity with CNB. Although FNAC remains
48 the preferred first-line test due to its low cost and invasiveness, the committee recognised
49 CNB as a better alternative for people who received a non-diagnostic cytology (Thy1) and, in
50 line with clinical and economic evidence, made an offer recommendation for CNB. The
51 committee were aware that, in some centres, CNB might not be a feasible alternative to
52 FNAC as radiologists may be trained to perform FNAC only and/or the nodule may be

1 located in a part of the neck that would make performing a CNB hazardous. Therefore, the
2 committee added an additional recommendation for FNAC if CNB is inappropriate or
3 unavailable. For further inadequate results after repeat sampling, a consider
4 recommendation for diagnostic hemithyroidectomy was made. This reflects the Committee's
5 view that people with Thy1 should not always undergo surgery, even when sequential tests
6 end up being non-diagnostic, as the risk of malignancy with this cytology remains relatively
7 low and additional clinical considerations should be assessed alongside when making a
8 decision.

9 Similarly to Thy1, the analysis on Thy3a found that CNB was the most cost effective strategy
10 compared to all the alternatives included. In the probabilistic analysis, the two CNB
11 strategies, CNB with selective use of molecular testing and CNB with selective use of
12 hemithyroidectomy, had together a probability of 65% of being cost effective and a higher
13 NMB than each alternative, including FNAC and hemithyroidectomy which reflects current
14 practice. In line with the evidence, the committee recommended CNB to be offered as the
15 preferred method of sampling after Thy3a, although room was left to use FNAC instead
16 based on local preference and availability as in the case of Thy1. In case of a further
17 inconclusive result, the results of the model indicate that selective use of hemithyroidectomy
18 is cost-effective compared to selective use of molecular testing with ThyroSeq V3.
19 Consequently, the committee decided to hemithyroidectomy or active surveillance when
20 repeat sampling gives a further inconclusive result.

21 Regarding the last category analysed Thy3f, routine use of molecular testing with ThyroSeq
22 V3 had a higher probability of being cost-effective (57%) but had a lower probabilistic NMB
23 than hemithyroidectomy highlighting the difference in uncertainty between these two
24 strategies: whereas hemithyroidectomy had a minimal level of uncertainty as it represents a
25 perfectly sensitive and specific test, the same is not true for molecular tests whose true
26 accuracy is uncertain and its cost in England is unclear being largely produced in the US.
27 The Committee acknowledged that the uncertainty on cost-effectiveness of molecular testing
28 after Thy3f would not allow to make a positive recommendation for this category, as it would
29 represent a very important deviation from current practice in England, where Thy3f is
30 generally followed-up with diagnostic hemithyroidectomy. Moreover, the risk of malignancy in
31 Thy3f is very significant, as around 30% of Thy3f nodules are found to be malignant after
32 surgery. The NHS has a 28 days target from referral to final diagnosis for cancer. As
33 molecular tests are not widely available in the UK, a positive recommendation for molecular
34 testing after Thy3f implies that a large number of samples would be shipped to laboratories
35 overseas at least in the short term, which is likely to significantly increase time between GP
36 referral and first treatment. This risks to lead several centres to fail in meeting the target
37 which may negatively affect wellbeing and risk of recurrent/persistent disease in people with
38 thyroid cancer.

39 Regarding the other RCPATH categories Thy2, Thy4 and Thy5, the Committee made
40 recommendations in line with current practice. Thy2 is the benign cytology and has the
41 lowest risk of malignancy: 5%. The committee made a recommendation in line with current
42 practice and latest BTS guidelines recommending repeat sampling with CNB or FNAC only if
43 there are clinical concerns on ultrasound (EU TIRADS > 4). Thy4 and Thy5 are the
44 suspicious and malignant categories with a risk of malignancy of, respectively, 79% and
45 98%. Given the very high cancer prevalence, the Committee recommended surgery, either
46 diagnosis or therapeutic, which appears to be strongly justified from a health economics point
47 of view due to the low number of false positives in these two categories.

48 **1.1.13 Recommendations supported by this evidence review**

49 This evidence review supports recommendations 1.2.15.

References

1. Castellana M, Trimboli P, Piccardo A, Giovanella L, Treglia G. Performance of 18f-fdg pet/ct in selecting thyroid nodules with indeterminate fine-needle aspiration cytology for surgery. A systematic review and a meta-analysis. *Journal of Clinical Medicine*. 2019; 8(9):28
2. Furlan JC, Bedard YC, Rosen IB. Single versus sequential fine-needle aspiration biopsy in the management of thyroid nodular disease. *Canadian Journal of Surgery*. 2005; 48(1):12-18
3. Gerhard R, Boerner SL. Evaluation of indeterminate thyroid cytology by second-opinion diagnosis or repeat fine-needle aspiration: which is the best approach? *Acta Cytologica*. 2015; 59(1):43-50
4. GRADE Working Group. The grading of recommendations assessment, development and evaluation (grade) working group website. 2011. Available from: <http://www.gradeworkinggroup.org/> Last accessed:
5. Health and Social Care Information Centre. Prescription cost analysis, England [updated December 2021]. Available from: <https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/prescription-cost-analysis-pca-data> Last accessed:
6. Joint Formulary Committee. *British National Formulary (BNF)*. 67th ed. London. British Medical Association and The Royal Pharmaceutical Society of Great Britain,. 2014. Available from: <http://www.bnf.org.uk>
7. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. *Cancer*. 2005; 103(7):1330-1335
8. Khoncarly SM, Tamarkin SW, McHenry CR. Can ultrasound be used to predict malignancy in patients with a thyroid nodule and an indeterminate fine-needle aspiration biopsy? *Surgery (United States)*. 2014; 156(4):967-971
9. Kuo JH, McManus C, Graves CE, Madani A, Khokhar MT, Huang B et al. Updates in the management of thyroid nodules. *Current Problems in Surgery*. 2019; 56(3):103-127
10. Labourier E, Shifrin A, Busseniers AE, Lupo MA, Manganelli ML, Andruss B et al. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. *The Journal of Clinical Endocrinology & Metabolism*. 2015; 100(7):2743-2750
11. Lee J, Kim BK, Sul HJ, Kim JO, Lee J, Sun WY. Negative pressure is not necessary for using fine-needle aspiration biopsy to diagnose suspected thyroid nodules: a prospective randomized study. *Annals of surgical treatment and research*. 2019; 96(5):216-222
12. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. *New England Journal of Medicine*. 2012; 366(18):1674-1685
13. National Institute for Health and Care Excellence. *Developing NICE guidelines: the manual*. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>

- 1 14. National Institute for Health and Clinical Excellence. Thyroid disease: assessment
2 and management NG145: Evidence Review [F] Monitoring thyroid disease. 2019.
3 Available from: <https://www.nice.org.uk/guidance/ng145>
- 4 15. NHS England and NHS Improvement. National Cost Collection Data Publication
5 2019-2020. London. 2020. Available from: [https://www.england.nhs.uk/wp-](https://www.england.nhs.uk/wp-content/uploads/2021/06/National-Cost-Collection-2019-20-Report-FINAL.pdf)
6 [content/uploads/2021/06/National-Cost-Collection-2019-20-Report-FINAL.pdf](https://www.england.nhs.uk/wp-content/uploads/2021/06/National-Cost-Collection-2019-20-Report-FINAL.pdf)
- 7 16. Nikiforov YE, Baloch ZW. Clinical validation of the ThyroSeq v3 genomic classifier in
8 thyroid nodules with indeterminate FNA cytology. *Cancer Cytopathology*. 2019;
9 127(4):225-230
- 10 17. Organisation for Economic Co-operation and Development (OECD). Purchasing
11 power parities (PPP). 2021. Available from: <http://www.oecd.org/std/ppp> Last
12 accessed: 24/03/2022.
- 13 18. Patel K, Patel A, Shah K, Patel N. FNAC is a primary diagnostic tool in thyroid
14 swelling. *Biosciences Biotechnology Research Asia*. 2014; 11(3):1873-1876
- 15 19. Pyo JS, Sohn JH, Kang G. Core needle biopsy is a more conclusive follow-up method
16 than repeat fine needle aspiration for thyroid nodules with initially inconclusive results:
17 A systematic review and meta-analysis. *Journal of Pathology & Translational*
18 *Medicine*. 2016; 50(3):217-224
- 19 20. Qiu Y, Xing Z, Liu J, Peng Y, Zhu J, Su A. Diagnostic reliability of elastography in
20 thyroid nodules reported as indeterminate at prior fine-needle aspiration cytology
21 (FNAC): a systematic review and Bayesian meta-analysis. *European Radiology*.
22 2020; 30(12):6624-6634
- 23 21. Romitelli F, Di Stasio E, Santoro C, Iozzino M, Orsini A, Cesareo R. A comparative
24 study of fine needle aspiration and fine needle non-aspiration biopsy on suspected
25 thyroid nodules. *Endocrine Pathology*. 2009; 20(2):108-113
- 26 22. Shrestha RT, Evasovich MR, Amin K, Radulescu A, Sanghvi TS, Nelson AC et al.
27 Correlation between histological diagnosis and mutational panel testing of thyroid
28 nodules: A two-year institutional experience. *Thyroid : official journal of the American*
29 *Thyroid Association*. 2016; 26(8):1068-1076
- 30 23. Straccia P, Rossi ED, Bizzarro T, Brunelli C, Cianfrini F, Damiani D et al. A meta-
31 analytic review of the Bethesda System for Reporting Thyroid Cytopathology: Has the
32 rate of malignancy in indeterminate lesions been underestimated? *Cancer*
33 *Cytopathology*. 2015; 123(12):713-722
- 34 24. Suh CH, Baek JH, Kim KW, Sung TY, Kim TY, Song DE et al. The role of core-needle
35 biopsy for thyroid nodules with initially nondiagnostic fine-needle aspiration results: A
36 systematic review and meta-analysis. *Endocrine Practice*. 2016; 22(6):679-688
- 37 25. Suh CH, Baek JH, Park C, Choi YJ, Lee JH. The role of core needle biopsy for
38 thyroid nodules with initially indeterminate results on previous fine-needle aspiration:
39 A systematic review and meta-analysis. *AJNR: American Journal of Neuroradiology*.
40 2017; 38(7):1421-1426
- 41 26. The British Association of Endocrine & Thyroid Surgeons. Sixth National Audit
42 Report. 2021. Available from: [https://www.baets.org.uk/wp-content/uploads/BAETS-](https://www.baets.org.uk/wp-content/uploads/BAETS-Sixth-Audit-Report-FINAL.pdf)
43 [Sixth-Audit-Report-FINAL.pdf](https://www.baets.org.uk/wp-content/uploads/BAETS-Sixth-Audit-Report-FINAL.pdf)
- 44 27. Trimboli P, Giovanella L. Reliability of core needle biopsy as a second-line procedure
45 in thyroid nodules with an indeterminate fine-needle aspiration report: a systematic
46 review and meta-analysis. *Ultrasonography*. 2018; 37(2):121-128

- 1 28. Trimboli P, Treglia G, Sadeghi R, Romanelli F, Giovanella L. Reliability of real-time
2 elastography to diagnose thyroid nodules previously read at FNAC as indeterminate:
3 a meta-analysis. *Endocrine*. 2015; 50(2):335-343
- 4 29. Valerio E, Pastorello RG, Calsavara V, Porfirio MM, Engelman GG, Francisco Dalcin
5 J et al. Should we wait 3 months for a repeat aspiration in non-
6 diagnostic/indeterminate thyroid nodules? A cancer centre experience.
7 *Cytopathology*. 2020; 31(6):525-532
- 8 30. van Roosmalen J, van Hemel B, Suurmeijer A, Groen H, Ruitenbeek T, Links TP et
9 al. Diagnostic value and cost considerations of routine fine-needle aspirations in the
10 follow-up of thyroid nodules with benign readings. *Thyroid*. 2010; 20(12):1359-1365
- 11 31. Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ, de Geus-Oei LF.
12 The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid
13 nodules with indeterminate fine-needle aspiration biopsy: systematic review and
14 meta-analysis of the literature. *Cancer*. 2011; 117(20):4582-4594
- 15 32. Wang N, Zhai H, Lu Y. Erratum: Is fluorine-18 fluorodeoxyglucose positron emission
16 tomography useful for the thyroid nodules with indeterminate fine needle aspiration
17 biopsy? A meta-analysis of the literature (*Journal of Otolaryngology - Head and Neck
18 Surgery* (2014) 43 (43)). *Journal of Otolaryngology Head and Neck Surgery*. 2014;
19 43(November)
- 20

1 Appendices

2 Appendix A – Review protocols

31.1.13.1 Review protocol for management strategy in people with indeterminate FNA

Field	Content
PROSPERO registration number	CRD42021244449
Review title	The clinical and cost effectiveness of diagnostic hemithyroidectomy, repeat FNAC, active surveillance or discharge, in people with fine-needle aspiration samples showing benign cytology or non-diagnostic features, but with US / clinical findings indicative of increased risk of malignancy.
Review question	For people with fine-needle aspiration samples showing benign cytology or non-diagnostic features but with US / clinical findings indicative of increased risk of malignancy, is it clinically and cost effective to use diagnostic hemithyroidectomy, repeat FNAC, use active surveillance or discharge?
Objective	To determine the best management strategy for people with indeterminate findings on FNAC
Searches	The following databases (from inception) will be searched: <ul style="list-style-type: none"> • Cochrane Central Register of Controlled Trials (CENTRAL) • Cochrane Database of Systematic Reviews (CDSR) • Embase • MEDLINE

	<p>Searches will be restricted by:</p> <ul style="list-style-type: none"> • English language • Human studies • Letters and comments are excluded. <p>Other searches:</p> <ul style="list-style-type: none"> • Inclusion lists of relevant systematic reviews will be checked by the reviewer. <p>The searches may be re-run 6 weeks before final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review.</p> <p>Medline search strategy to be quality assured using the PRESS evidence-based checklist (see methods chapter for full details).</p>
Condition or domain being studied	Thyroid cancer
Population	<p>Inclusion:</p> <p>People aged 16 or over who are suspected of having thyroid cancer. They have fine-needle aspiration samples showing benign cytology or non-diagnostic atypical features but have US / clinical findings indicative of increased risk of malignancy</p> <p>Exclusion:</p> <p>Children and young people under 16 years</p>

Intervention	<ul style="list-style-type: none"> • diagnostic hemithyroidectomy • repeat FNAC • active surveillance • discharge without active surveillance
Comparator	Each other
Types of study to be included	<ul style="list-style-type: none"> • Systematic reviews • RCTs <p>Non-randomised studies will be excluded.</p>
Other exclusion criteria	<p>Non-English language studies.</p> <p>Conference abstracts will be excluded as it is expected there will be sufficient full text published studies available.</p> <p>People with indications for surgery other than risk of malignancy (such as hyperthyroidism, pressure effects)</p>
Context	Occasionally there is uncertainty when FNAC results are benign or non-diagnostic but high clinical suspicion of cancer remains based on clinical findings or US findings. This question aims to compare the possible courses of action in this scenario to enable recommendation of the best approach.
Primary outcomes (critical outcomes)	<p>All outcomes are considered equally important for decision making and therefore have all been rated as critical:</p> <p>mortality</p> <ul style="list-style-type: none"> • quality of life (any validated scores)

	<ul style="list-style-type: none"> thyroid cancer diagnosis <p>Time of follow up: longest available</p>
Data extraction (selection and coding)	<p>EndNote will be used for reference management, sifting, citations and bibliographies. Titles and/or abstracts of studies retrieved using the search strategy and those from additional sources will be screened for inclusion.</p> <p>10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer.</p> <p>The full text of potentially eligible studies will be retrieved and will be assessed for eligibility in line with the criteria outlined above.</p> <ul style="list-style-type: none"> 10% of all evidence reviews are quality assured by a senior research fellow. This includes checking: <ul style="list-style-type: none"> papers were included /excluded appropriately a sample of the data extractions correct methods are used to synthesise data a sample of the risk of bias assessments <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p> <p>An in-house developed database; EviBase, will be used for data extraction. A standardised form is followed to extract data from studies (see Developing NICE guidelines: the manual section 6.4) and for undertaking assessment of study quality. Summary evidence tables will be produced including information on: study setting; study population and participant demographics and baseline characteristics; details of the intervention and control interventions; study methodology' recruitment and missing data rates; outcomes and times of measurement; critical appraisal ratings.</p>

<p>Risk of bias (quality) assessment</p>	<p>Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.</p> <p>For Intervention reviews the following checklist will be used according to study design being assessed:</p> <ul style="list-style-type: none"> • Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS) • Randomised Controlled Trial: Cochrane RoB (2.0)
<p>Strategy for data synthesis</p>	<p>Where possible, data will be meta-analysed. Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5) to combine the data given in all studies for each of the outcomes stated above. A fixed effect meta-analysis, with weighted mean differences for continuous outcomes and risk ratios for binary outcomes will be used, and 95% confidence intervals will be calculated for each outcome.</p> <p>Heterogeneity between the studies in effect measures will be assessed using the I^2 statistic and visually inspected. We will consider an I^2 value greater than 50% indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented using random-effects.</p> <p>GRADE pro will be used to assess the quality of each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome.</p> <p>Publication bias is tested for when there are more than 5 studies for an outcome. Other bias will only be taken into consideration in the quality assessment if it is apparent.</p> <p>Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome.</p>

	If sufficient data is available to make a network of treatments, WinBUGS will be used for network meta-analysis.
Analysis of sub-groups	<p><u>Stratification</u> None</p> <p><u>Sub-grouping</u> If serious or very serious heterogeneity ($I^2 > 50\%$) is present within any stratum, sub-grouping will occur according to the following strategies:</p> <ul style="list-style-type: none"> • Benign vs inadequate vs indeterminate (based on FNA findings) • Indeterminate vs suspicious (based on US findings) • Size of nodule (<4cm, >=4cm)
Type and method of review	<input checked="" type="checkbox"/> Intervention <input type="checkbox"/> Diagnostic <input type="checkbox"/> Prognostic <input type="checkbox"/> Qualitative <input type="checkbox"/> Epidemiologic <input type="checkbox"/> Service Delivery <input type="checkbox"/> Other (please specify)
Language	English
Country	England
Named contact	Named contact

	<p>National Guideline Centre</p> <p>Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and the National Guideline Centre</p>
Review team members	<p>From the National Guideline Centre:</p> <p>Carlos Sharpin, Guideline lead Mark Perry, Senior systematic reviewer Alfredo Mariani, Health economist Lina Gulhane, Head of Information specialists</p>
Funding sources/sponsor	<p>This systematic review is being completed by the National Guideline Centre which receives funding from NICE.</p>
Conflicts of interest	<p>All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.</p>
Collaborators	<p>Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of Developing NICE guidelines: the manual. Members of the guideline committee</p>

	are available on the NICE website: https://www.nice.org.uk/guidance/indevelopment/gid-ng10150/documents
Other registration details	N/A
Reference/URL for published protocol	https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=244449
Dissemination plans	<p>NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:</p> <ul style="list-style-type: none"> • notifying registered stakeholders of publication • publicising the guideline through NICE's newsletter and alerts • issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.
Keywords	Thyroid cancer
Details of existing review of same topic by same authors	N/A
Additional information	N/A
Details of final publication	www.nice.org.uk

11.1.13.2 Review protocol health economic evidence

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see Appendix B below.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2005, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).¹³</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’, then it will be included in the guideline. A health economic evidence table will be completed, and it will be included in the health economic evidence profile. • If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’, then it will usually be excluded from the guideline. If it is excluded, then a health economic evidence table will not be completed, and it will not be included in the health economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included. <p>Where there is discretion</p>

The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2005 or later but that depend on unit costs and resource data entirely or predominantly from before 2005 will be rated as 'Not applicable'.
- Studies published before 2005 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

1

2

Appendix B – Literature search strategies

3

4

5

6

The literature searches for these reviews are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual, 2014 (updated 2020) <https://www.nice.org.uk/process/pmg20/chapter/identifying-the-evidence-literature-searching-and-evidence-submission>.

7

8

For more information, please see the Methodology review published as part of the accompanying documents for this guideline.

9

Clinical literature search strategy

10

This literature search strategy was used for the following reviews:

11

12

13

14

- For people with fine-needle aspiration samples showing benign cytology or non-diagnostic features but with US / clinical findings indicative of increased risk of malignancy, is it clinically and cost effective to use diagnostic hemithyroidectomy, repeat FNAC, use active surveillance or discharge?

15

16

17

18

19

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.

20

Table 6: Database parameters, filters and limits applied

Database	Dates searched	Search filters and limits applied
Medline (OVID)	1946 – 13 January 2022	Randomised controlled trials Systematic review studies Observational studies Diagnostic studies Exclusions (animal studies, letters, comments, editorials, case studies/reports, children) English language
Embase (OVID)	1974 – 13 January 2022	Randomised controlled trials Systematic review studies Observational studies Diagnostic studies Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts, children) English language
The Cochrane Library (Wiley)	Cochrane Database of Systematic Reviews to Issue 12 of 12, December 2021	Exclusions (clinical trials, conference abstracts)

Database	Dates searched	Search filters and limits applied
	Cochrane Central Register of Controlled Trials to Issue 12 of 12, December 2021	
Epistemonikos (The Epistemonikos Foundation)	Inception – 13 January 2022	Systematic review Exclusions (Cochrane reviews) English language

1

Medline (Ovid) search terms

1.	exp Thyroid Neoplasms/
2.	(thyroid adj3 (cancer* or carcinom* or microcarcinoma* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or node* or nodul* or nodal or lump* or papillar* or swollen or swell* or anaplastic or sarcoma* or cyst* or malignan*)).ti,ab.
3.	DTC.ti,ab.
4.	((papillar* or anaplastic) adj2 (cancer* or carcinom* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or nodul* or node* or lump*)).ti,ab.
5.	or/1-4
6.	letter/
7.	editorial/
8.	news/
9.	exp historical article/
10.	Anecdotes as Topic/
11.	comment/
12.	case report/
13.	(letter or comment*).ti.
14.	or/6-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animals/ not humans/
18.	exp Animals, Laboratory/
19.	exp Animal Experimentation/
20.	exp Models, Animal/
21.	exp Rodentia/
22.	(rat or rats or mouse or mice or rodent*).ti.
23.	or/16-22
24.	5 not 23
25.	limit 24 to english language
26.	(exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)
27.	25 not 26
28.	exp Biopsy, Needle/
29.	((needle or core or puncture) adj3 (aspirat* or biops* or cytology)).ti,ab.
30.	(FNAC or FNA or FNAB or FNB or FNC or CNB).ti,ab.
31.	or/28-30
32.	27 and 31
33.	randomized controlled trial.pt.

34.	controlled clinical trial.pt.
35.	randomi#ed.ab.
36.	placebo.ab.
37.	randomly.ab.
38.	clinical trials as topic.sh.
39.	trial.ti.
40.	or/33-39
41.	Meta-Analysis/
42.	Meta-Analysis as Topic/
43.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
44.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
45.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
46.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
47.	(search* adj4 literature).ab.
48.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
49.	cochrane.jw.
50.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
51.	or/41-50
52.	32 and (40 or 51)
53.	Epidemiologic studies/
54.	Observational study/
55.	exp Cohort studies/
56.	(cohort adj (study or studies or analys* or data)).ti,ab.
57.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
58.	((longitudinal or retrospective or prospective) and (study or studies or review or analys* or cohort* or data)).ti,ab.
59.	Controlled Before-After Studies/
60.	Historically Controlled Study/
61.	Interrupted Time Series Analysis/
62.	(before adj2 after adj2 (study or studies or data)).ti,ab.
63.	exp case control study/
64.	case control*.ti,ab.
65.	Cross-sectional studies/
66.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
67.	or/53-66
68.	32 and 67
69.	68 not 52
70.	exp "sensitivity and specificity"/
71.	(sensitivity or specificity).ti,ab.
72.	((pre test or pretest or post test) adj probability).ti,ab.
73.	(predictive value* or PPV or NPV).ti,ab.
74.	likelihood ratio*.ti,ab.
75.	likelihood function/
76.	((area under adj4 curve) or AUC).ti,ab.

77.	(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.
78.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
79.	gold standard.ab.
80.	exp Diagnostic errors/
81.	(false positiv* or false negativ*).tw.
82.	or/70-81
83.	32 and 82
84.	83 not (52 or 69)

1

Embase (Ovid) search terms

1.	exp Thyroid Cancer/
2.	(thyroid adj3 (cancer* or carcinom* or microcarcinoma* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or node* or nodul* or nodal or lump* or papillar* or swollen or swell* or anaplastic or sarcoma* or cyst* or malignan*)).ti,ab.
3.	DTC.ti,ab.
4.	((papillar* or anaplastic) adj2 (cancer* or carcinom* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or nodul* or node* or lump*)).ti,ab.
5.	or/1-4
6.	letter.pt. or letter/
7.	note.pt.
8.	editorial.pt.
9.	case report/ or case study/
10.	(letter or comment*).ti.
11.	(conference abstract or conference paper).pt.
12.	or/6-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental Animal/
19.	animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice or rodent*).ti.
22.	or/14-21
23.	5 not 22
24.	limit 23 to english language
25.	(exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/)
26.	24 not 25
27.	exp Needle Biopsy/
28.	((needle or core or puncture) adj3 (aspirat* or biops* or cytology)).ti,ab.
29.	(FNAC or FNA or FNAB or FNB or FNC or CNB).ti,ab.
30.	or/27-29
31.	26 and 30
32.	random*.ti,ab.
33.	factorial*.ti,ab.
34.	(crossover* or cross over*).ti,ab.
35.	((doubl* or singl*) adj blind*).ti,ab.

36.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
37.	crossover procedure/
38.	single blind procedure/
39.	randomized controlled trial/
40.	double blind procedure/
41.	or/32-40
42.	systematic review/
43.	Meta-Analysis/
44.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
45.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
46.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
47.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
48.	(search* adj4 literature).ab.
49.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
50.	cochrane.jw.
51.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
52.	or/42-51
53.	31 and (41 or 52)
54.	Clinical study/
55.	Observational study/
56.	family study/
57.	longitudinal study/
58.	retrospective study/
59.	prospective study/
60.	cohort analysis/
61.	follow-up/
62.	cohort*.ti,ab.
63.	61 and 62
64.	(cohort adj (study or studies or analys* or data)).ti,ab.
65.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
66.	((longitudinal or retrospective or prospective) and (study or studies or review or analys* or cohort* or data)).ti,ab.
67.	(before adj2 after adj2 (study or studies or data)).ti,ab.
68.	exp case control study/
69.	case control*.ti,ab.
70.	cross-sectional study/
71.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
72.	or/54-60,63-71
73.	31 and 72
74.	73 not 53
75.	exp "sensitivity and specificity"/
76.	(sensitivity or specificity).ti,ab.
77.	((pre test or pretest or post test) adj probability).ti,ab.
78.	(predictive value* or PPV or NPV).ti,ab.

79.	likelihood ratio*.ti,ab.
80.	((area under adj4 curve) or AUC).ti,ab.
81.	(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.
82.	diagnostic accuracy/
83.	diagnostic test accuracy study/
84.	gold standard.ab.
85.	exp diagnostic error/
86.	(false positiv* or false negativ*).ti,ab.
87.	differential diagnosis/
88.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness or precision or validat* or validity or differential or error*).ti,ab.
89.	or/75-88
90.	31 and 89
91.	90 not (53 or 74)

1

Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Thyroid Neoplasms] explode all trees
#2.	(thyroid near/3 (cancer* or carcinom* or microcarcinoma* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or node* or nodul* or nodal or lump* or papillar* or swollen or swell* or anaplastic or sarcoma* or cyst* or malignan*)):ti,ab
#3.	DTC:ti,ab
#4.	((papillar* or anaplastic) near/2 (cancer* or carcinom* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or nodul* or node* or lump*)):ti,ab
#5.	#1 or #2 or #3 or #4
#6.	MeSH descriptor: [Biopsy, Needle] explode all trees
#7.	(needle or core or puncture) near/3 (aspirat* or biops* or cytology):ti,ab
#8.	(FNAC or FNA or FNAB or FNB or FNC or CNB):ti,ab
#9.	#6 or #7 or #8
#10.	#5 and #9
#11.	conference:pt or (clinicaltrials or trialsearch):so
#12.	#10 not #11

2

3

Epistemonikos search terms

1.	(title:(thyroid AND (cancer* OR neoplasm* OR nodule* OR carcinoma*)) OR abstract:(thyroid AND (cancer* OR neoplasm* OR nodule* OR carcinoma*))) AND (title:(needle OR puncture OR biops* OR aspirat*) OR abstract:(needle OR puncture OR biops* OR aspirat*)) OR abstract:(title:(thyroid AND (cancer* OR neoplasm* OR nodule* OR carcinoma*)) OR abstract:(thyroid AND (cancer* OR neoplasm* OR nodule* OR carcinoma*))) AND (title:(needle OR puncture OR biops* OR aspirat*) OR abstract:(needle OR puncture OR biops* OR aspirat*))
----	---

4

Health Economics literature search strategy

5 Health economic evidence was identified by conducting searches using terms for a broad
6 Thyroid Cancer population. The following databases were searched: NHS Economic
7 Evaluation Database (NHS EED - this ceased to be updated after 31st March 2015), Health
8 Technology Assessment database (HTA - this ceased to be updated from 31st March 2018)
9 and The International Network of Agencies for Health Technology Assessment (INAHTA).
10 Searches for recent evidence were run on Medline and Embase from 2014 onwards for
11 health economics, and all years for quality-of-life studies.

1

Table 2: Database parameters, filters and limits applied

Database	Dates searched	Search filters and limits applied
Medline (OVID)	Health Economics 1 January 2014 – 16 December 2021	Health economics studies Quality of life studies
	Quality of Life 1946 – 16 December 2021	Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts) English language
Embase (OVID)	Health Economics 1 January 2014 – 16 December 2021	Health economics studies Quality of life studies
	Quality of Life 1974 – 16 December 2021	Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts) English language
NHS Economic Evaluation Database (NHS EED) (Centre for Research and Dissemination - CRD)	Inception – 31 st March 2015	
Health Technology Assessment Database (HTA) (Centre for Research and Dissemination – CRD)	Inception – 31 st March 2018	
The International Network of Agencies for Health Technology Assessment (INAHTA)	Inception - 16 December 2021	English language

2

Medline (Ovid) search terms

1.	exp Thyroid Neoplasms/
2.	(thyroid adj4 (cancer* or carcinom* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or papillar* or follicul* or lymphoma* or anaplastic)).ti,ab.
3.	((papillar* or follicul* or medullary or anaplastic) adj4 (cancer* or carcinom* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or lymphoma*)).ti,ab.
4.	or/1-3
5.	letter/
6.	editorial/
7.	news/
8.	exp historical article/
9.	Anecdotes as Topic/
10.	comment/
11.	case report/
12.	(letter or comment*).ti.
13.	or/5-12

14.	randomized controlled trial/ or random*.ti,ab.
15.	13 not 14
16.	animals/ not humans/
17.	exp Animals, Laboratory/
18.	exp Animal Experimentation/
19.	exp Models, Animal/
20.	exp Rodentia/
21.	(rat or rats or mouse or mice).ti.
22.	or/15-21
23.	4 not 22
24.	limit 23 to english language
25.	economics/
26.	value of life/
27.	exp "costs and cost analysis"/
28.	exp Economics, Hospital/
29.	exp Economics, medical/
30.	Economics, nursing/
31.	economics, pharmaceutical/
32.	exp "Fees and Charges"/
33.	exp budgets/
34.	budget*.ti,ab.
35.	cost*.ti.
36.	(economic* or pharmaco?economic*).ti.
37.	(price* or pricing*).ti,ab.
38.	(cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
39.	(financ* or fee or fees).ti,ab.
40.	(value adj2 (money or monetary)).ti,ab.
41.	or/25-40
42.	24 and 41
43.	quality-adjusted life years/
44.	sickness impact profile/
45.	(quality adj2 (wellbeing or well being)).ti,ab.
46.	sickness impact profile.ti,ab.
47.	disability adjusted life.ti,ab.
48.	(qal* or qtime* or qwb* or daly*).ti,ab.
49.	(euroqol* or eq5d* or eq 5*).ti,ab.
50.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
51.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
52.	(hui or hui1 or hui2 or hui3).ti,ab.
53.	(health* year* equivalent* or hye or hyes).ti,ab.
54.	discrete choice*.ti,ab.
55.	rosser.ti,ab.
56.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
57.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
58.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
59.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
60.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.

61.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
62.	or/52-70
63.	24 and 62

1

Embase (Ovid) search terms

1.	exp Thyroid Cancer/
2.	(thyroid adj4 (cancer* or carcinom* or tumo?r* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or papillar* or follicul* or lymphoma* or anaplastic)).ti,ab.
3.	((papillar* or follicul* or medullary or anaplastic) adj4 (cancer* or carcinom* or tumo?r* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or lymphoma*)).ti,ab.
4.	or/1-3
5.	letter.pt. or letter/
6.	note.pt.
7.	editorial.pt.
8.	case report/ or case study/
9.	(letter or comment*).ti.
10.	or/5-9
11.	randomized controlled trial/ or random*.ti,ab.
12.	10 not 11
13.	animal/ not human/
14.	nonhuman/
15.	exp Animal Experiment/
16.	exp Experimental Animal/
17.	animal model/
18.	exp Rodent/
19.	(rat or rats or mouse or mice).ti.
20.	or/12-19
21.	4 not 20
22.	limit 21 to english language
23.	health economics/
24.	exp economic evaluation/
25.	exp health care cost/
26.	exp fee/
27.	budget/
28.	funding/
29.	budget*.ti,ab.
30.	cost*.ti.
31.	(economic* or pharmaco?economic*).ti.
32.	(price* or pricing*).ti,ab.
33.	(cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
34.	(financ* or fee or fees).ti,ab.
35.	(value adj2 (money or monetary)).ti,ab.
36.	or/23-35
37.	22 and 36
38.	quality-adjusted life years/
39.	"quality of life index"/

40.	short form 12/ or short form 20/ or short form 36/ or short form 8/
41.	sickness impact profile/
42.	(quality adj2 (wellbeing or well being)).ti,ab.
43.	sickness impact profile.ti,ab.
44.	disability adjusted life.ti,ab.
45.	(qal* or qtime* or qwb* or daly*).ti,ab.
46.	(euroqol* or eq5d* or eq 5*).ti,ab.
47.	(qol* or hqi* or hqi* or h qol* or hrqol* or hr qol*).ti,ab.
48.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
49.	(hui or hui1 or hui2 or hui3).ti,ab.
50.	(health* year* equivalent* or hye or hyes).ti,ab.
51.	discrete choice*.ti,ab.
52.	rosser.ti,ab.
53.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
54.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
55.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
56.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
57.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
58.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
59.	or/37-58
60.	22 and 59

1

NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Thyroid Neoplasms EXPLODE ALL TREES
#2.	((thyroid NEAR4 (cancer* or carcinom* or tumour* or tumor* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or papillar* or follicul* or lymphoma* or anaplastic)))
#3.	((((papillar* or follicul* or medullary or anaplastic) NEAR4 (cancer* or carcinom* or tumour* or tumor* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or lymphoma*)))
#4.	#1 OR #2 OR #3

2

INHATA search terms

1.	(Thyroid Neoplasms)[mh] OR (thyroid neoplasms) AND (thyroid cancers)
----	--


3

4

5

1 Appendix C – Effectiveness evidence study selection

2 Figure 1: Flow chart of clinical study selection for the review of management strategy in
3 people with indeterminate FNA



4
5
6
7

Appendix D – Effectiveness evidence

No evidence was identified.


Appendix E – Forest plots

No evidence was identified.

Appendix F – GRADE and/or GRADE-CERQual tables

No evidence was identified.

Appendix G – Economic evidence study selection



* Non-relevant population, intervention, comparison, design or setting; non-English language

1

2

Appendix H – Economic evidence tables

Study	Furlan 2005 ²			
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness
<p>Economic analysis: Cost consequence (health outcome: None)</p> <p>Study design: Retrospective chart review of patients who underwent surgery at one hospital between 1998 and 2000</p> <p>Approach to analysis: FNA biopsy reports of 'suspicious for malignancy', 'follicular lesion', and 'cellular atypia' were considered positive and used to calculate accuracy, sensitivity, specificity, and costs.</p> <p>Perspective: Canadian healthcare system</p> <p>Time horizon: 2 years</p> <p>Discounting: Costs: NR</p>	<p>Population: Adults with suspected differentiated thyroid cancer and non-diagnostic or benign findings following FNA biopsy</p> <p>Cohort settings: Median age: 47 years Male: 16% N: 268</p> <p>Intervention 1: Single FNA biopsy (includes the first cytological evaluation from individuals who later underwent sequential FNA biopsies.</p> <p>Intervention 2: Sequential FNA biopsy (at least 2 cytological aspirations from the same patient on different dates over ≥1 year)</p>	<p>Total costs (mean per patient): Intervention 1: £47 Intervention 2: £80 Incremental (2-1): £33 (95% CI: NR; p=NR)</p> <p>Currency & cost year: 2004 Canadian dollars (presented here as 2004 UK pounds^(a))</p> <p>Cost components incorporated: FNA biopsy</p>	<p>Diagnostic outcomes (mean per group): Intervention 1:</p> <ul style="list-style-type: none"> • Accuracy: 63.8% • Sensitivity: 73.8% • Specificity: 69.0% <p>Intervention 2:</p> <ul style="list-style-type: none"> • Accuracy: 78.2% • Sensitivity: 84.0% • Specificity: 73.3% <p>Incremental (2-1)</p> <ul style="list-style-type: none"> • Accuracy: 14.4% • Sensitivity: 10.2% • Specificity: 4.3% 	<p>Sequential FNA biopsy was 70% more costly compared with single FNA biopsy and resulted in fewest number of false diagnoses.</p> <p>Analysis of uncertainty: Exclusion of all incidental microcarcinomas of 10mm or less found after thyroidectomy did not result in any significant differences in diagnostic accuracy (p=0.898); sensitivity (p=0.965); or specificity (0.594).</p>

Outcomes: NR

Data sources

Health outcomes: Accuracy of FNA biopsy was defined as the ratio between the number of true results and number of patients undergoing aspiration. Sensitivity was defined as the ratio between the number of patients with a positive cytology result and cancer at histology (true-positive results), and the number of patients with carcinoma at definitive histopathological report (true-positive plus false-negative results). Specificity was defined as the ratio between the number of patients with a negative cytological diagnosis as well as no tumour at histology (true negative results) and the number of patients with no carcinoma at histology (true-negative plus false negative results). **Quality-of-life weights:** NA **Cost sources:** Healthcare costs were estimated using the Ontario Health Insurance Plan schedule of benefits and fees.

Comments

Source of funding: The Head and Neck Cancer Foundation **Limitations:** Canadian healthcare context. Discount rate was not reported for a study with a time horizon of 2 years. Patients were not randomized to treatment groups and had statistically significant differences in baseline patient characteristics between groups. Mortality, quality of life, and other patient outcomes were not included. Study is non-randomized, sample size is small and study was conducted at one hospital with unclear generalizability. Analysis did not include costs of surgery and other downstream costs and consequences of diagnosis. Cost year not specified; assumed to be the date of the published source used to obtain unit costs. Sensitivity analyses were not included. The study is relatively old. Accuracy of FNAC may have been improved during the last two decades **Other:** None

Overall applicability:^(b) Partially applicable **Overall quality:**^(c) Potentially serious limitations

Abbreviations: 95% CI= 95% confidence interval; da= deterministic analysis; EQ-5D= Euroqol 5 dimensions (scale: 0.0 [death] to 1.0 [full health], negative values mean worse than death); ICER= incremental cost-effectiveness ratio; NA = not applicable; NR= not reported; pa= probabilistic analysis; QALYs= quality-adjusted life years; rhTSH = recombinant human thyroid stimulating hormone

(a) Converted using 2004/05 purchasing power parities¹⁷

(b) Directly applicable / Partially applicable / Not applicable

(c) Minor limitations / Potentially serious limitations / Very serious limitations

1
2
3
4
5
6

Appendix I – Excluded studies

I.1 Clinical studies

Table 7: Studies excluded from the clinical review

Study	Exclusion reason
Castellana 2019 ¹	Systematic review: study designs inappropriate
Gerhard 2015 ³	Systematic review: study designs inappropriate
Khoncarly 2014 ⁸	Incorrect study design: case series
Lee 2019 ¹¹	Not review population. Inappropriate comparison
Pyo 2016 ¹⁹	Systematic review: study designs inappropriate
Qiu 2020 ²⁰	Systematic review: study designs inappropriate. Incorrect interventions
Romitelli 2009 ²¹	Wrong comparison: fine needle aspiration versus fine needle non-aspiration
Straccia 2015 ²³	Systematic review: study designs inappropriate
Suh 2016 ²⁴	Systematic review: study designs inappropriate
Suh 2017 ²⁵	Systematic review: study designs inappropriate
Trimboli 2015 ²⁸	Systematic review: study designs inappropriate
Trimboli 2018 ²⁷	Systematic review: study designs inappropriate
Valerio 2020 ²⁹	Incorrect study design: retrospective observational study
Vriens 2011 ³¹	Systematic review: study designs inappropriate
Wang 2014 ³²	Systematic review: study designs inappropriate

I.2 Health Economic studies

Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2005 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.

Table 8: Studies excluded from the health economic review

Reference	Reason for exclusion
Van Roosmalen ⁴	Excludes as rated with very serious limitations. Patients were not randomized to either treatment group and the analysis was not adjusted for confounding factors.